GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
CEO Marc Hertz, PhD, will deliver a presentation and engage in one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for registered attendees. The webcast will also be accessible on the company's website and archived for 90 days post-event.
GRI Bio (NASDAQ: GRI), una compagnia biotecnologica focalizzata nello sviluppo di modulatori delle cellule Natural Killer T (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York, NY.
Il CEO Marc Hertz, PhD, presenterà un intervento e parteciperà a incontri individuali con investitori qualificati. Una trasmissione video della presentazione sarà disponibile on-demand a partire dal 9 settembre 2024, alle 7:00 AM ET per i partecipanti registrati. La trasmissione sarà inoltre accessibile sul sito web dell'azienda e archiviata per 90 giorni dopo l'evento.
GRI Bio (NASDAQ: GRI), una empresa de biotecnología enfocada en desarrollar moduladores de células Natural Killer T (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024 en Nueva York, NY.
El CEO Marc Hertz, PhD, realizará una presentación y participará en reuniones individuales con inversores calificados. Una transmisión de video de la presentación estará disponible bajo demanda a partir del 9 de septiembre de 2024, a las 7:00 AM ET para los asistentes registrados. La transmisión también será accesible en el sitio web de la empresa y se archivará durante 90 días después del evento.
GRI Bio (NASDAQ: GRI)는 염증, 섬유증 및 자가면역 질환 치료를 위한 자연 살해 T(NKT) 세포 조절제 개발에 중점을 둔 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참석한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열립니다.
CEO Marc Hertz, PhD는 발표를 하고 자격을 갖춘 투자자들과 개별 미팅에 참여할 예정입니다. 발표의 비디오 웹캐스트는 등록된 참석자를 위해 2024년 9월 9일 오전 7:00 ET부터 온디맨드로 제공될 예정입니다. 웹캐스트는 회사 웹사이트에서도 접근 가능하며, 이벤트 종료 후 90일 동안 아카이브됩니다.
GRI Bio (NASDAQ: GRI), une entreprise biotechnologique axée sur le développement de modulateurs de cellules Natural Killer T (NKT) pour les maladies inflammatoires, fibreuses et auto-immunes, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Cet événement se déroulera du 9 au 11 septembre 2024 à New York, NY.
Le PDG Marc Hertz, PhD, fera une présentation et participera à des réunions individuelles avec des investisseurs qualifiés. Un webinaire vidéo de la présentation sera disponible à la demande à partir du 9 septembre 2024 à 7h00 ET pour les participants enregistrés. Le webinaire sera également accessible sur le site Web de l'entreprise et archivé pendant 90 jours après l'événement.
GRI Bio (NASDAQ: GRI), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Modulatoren für natürliche Killer-T-Zellen (NKT) zur Behandlung von Entzündungen, Fibrose und Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der 26. Jahreskonferenz für globale Investitionen von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York, NY, statt.
Der CEO Marc Hertz, PhD wird eine Präsentation halten und individuelle Gespräche mit qualifizierten Investoren führen. Ein Video-Webcast der Präsentation wird ab dem 9. September 2024 um 7:00 Uhr ET für registrierte Teilnehmer on-demand verfügbar sein. Der Webcast wird zudem auf der Unternehmenswebsite zugänglich sein und 90 Tage nach der Veranstaltung archiviert werden.
- None.
- None.
LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (gribio.com). The webcast replay will be archived for 90 days following the event.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
When is GRI Bio presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for GRI Bio at the investment conference?
How can investors access GRI Bio's presentation at the conference?
What is the focus of GRI Bio's research and development?
How long will the webcast of GRI Bio's presentation be available?
